Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Medicare Part D | 23 | 2022 | 355 | 4.800 |
Why?
|
Telemedicine | 37 | 2024 | 3110 | 4.500 |
Why?
|
Opioid-Related Disorders | 23 | 2024 | 2188 | 4.060 |
Why?
|
Health Expenditures | 39 | 2024 | 2390 | 3.380 |
Why?
|
Insurance Coverage | 44 | 2024 | 1945 | 3.380 |
Why?
|
Insurance Benefits | 18 | 2022 | 185 | 3.130 |
Why?
|
Buprenorphine | 13 | 2024 | 667 | 3.070 |
Why?
|
Mental Health Services | 27 | 2024 | 1733 | 2.880 |
Why?
|
Nursing Homes | 15 | 2022 | 1084 | 2.440 |
Why?
|
Drug Costs | 21 | 2023 | 1196 | 2.250 |
Why?
|
Drug Prescriptions | 22 | 2024 | 1664 | 2.250 |
Why?
|
Drugs, Generic | 9 | 2023 | 457 | 2.180 |
Why?
|
Mental Disorders | 34 | 2024 | 6873 | 2.150 |
Why?
|
Alcoholism | 8 | 2024 | 1980 | 2.150 |
Why?
|
Medicare | 59 | 2024 | 6813 | 2.130 |
Why?
|
Insurance, Pharmaceutical Services | 17 | 2018 | 348 | 2.040 |
Why?
|
Health Benefit Plans, Employee | 13 | 2023 | 332 | 2.000 |
Why?
|
Patient Protection and Affordable Care Act | 12 | 2022 | 1188 | 1.860 |
Why?
|
Blue Cross Blue Shield Insurance Plans | 5 | 2018 | 92 | 1.840 |
Why?
|
Prescription Drugs | 10 | 2022 | 635 | 1.830 |
Why?
|
Hospices | 9 | 2020 | 245 | 1.800 |
Why?
|
Medicaid | 32 | 2024 | 2836 | 1.780 |
Why?
|
Formularies as Topic | 10 | 2019 | 94 | 1.780 |
Why?
|
Antipsychotic Agents | 15 | 2023 | 3078 | 1.740 |
Why?
|
Substance-Related Disorders | 26 | 2024 | 4422 | 1.620 |
Why?
|
United States | 176 | 2024 | 72971 | 1.600 |
Why?
|
Insurance, Health | 24 | 2024 | 2519 | 1.450 |
Why?
|
Drug Utilization | 20 | 2020 | 1190 | 1.390 |
Why?
|
Health Services Accessibility | 28 | 2023 | 5519 | 1.380 |
Why?
|
Ownership | 5 | 2020 | 338 | 1.280 |
Why?
|
Opiate Substitution Treatment | 9 | 2024 | 452 | 1.270 |
Why?
|
Prescription Fees | 8 | 2020 | 153 | 1.260 |
Why?
|
Deductibles and Coinsurance | 11 | 2024 | 315 | 1.210 |
Why?
|
Hospice Care | 7 | 2018 | 678 | 1.160 |
Why?
|
Managed Care Programs | 14 | 2013 | 939 | 1.110 |
Why?
|
Insurance Claim Review | 11 | 2018 | 744 | 1.090 |
Why?
|
Mental Health | 13 | 2024 | 3272 | 1.030 |
Why?
|
Psychotropic Drugs | 8 | 2022 | 881 | 1.010 |
Why?
|
Benzodiazepines | 4 | 2023 | 1137 | 0.970 |
Why?
|
Homes for the Aged | 3 | 2022 | 273 | 0.930 |
Why?
|
Contract Services | 4 | 2020 | 90 | 0.930 |
Why?
|
Terminal Care | 12 | 2018 | 1770 | 0.900 |
Why?
|
Biochemical Phenomena | 1 | 2024 | 58 | 0.900 |
Why?
|
Pandemics | 20 | 2024 | 8736 | 0.880 |
Why?
|
Reimbursement, Incentive | 5 | 2016 | 541 | 0.860 |
Why?
|
Cost Sharing | 8 | 2020 | 409 | 0.830 |
Why?
|
Narcotic Antagonists | 4 | 2023 | 591 | 0.830 |
Why?
|
Assisted Living Facilities | 1 | 2022 | 27 | 0.790 |
Why?
|
Antidepressive Agents | 10 | 2017 | 2912 | 0.790 |
Why?
|
Bipolar Disorder | 11 | 2024 | 5130 | 0.740 |
Why?
|
Humans | 230 | 2024 | 767040 | 0.730 |
Why?
|
Fee-for-Service Plans | 11 | 2022 | 713 | 0.720 |
Why?
|
Medically Uninsured | 4 | 2020 | 838 | 0.690 |
Why?
|
Analgesics, Opioid | 9 | 2024 | 3837 | 0.660 |
Why?
|
Psychiatry | 11 | 2022 | 1715 | 0.650 |
Why?
|
Nurse Practitioners | 4 | 2023 | 271 | 0.650 |
Why?
|
Unemployment | 1 | 2020 | 211 | 0.620 |
Why?
|
Drug Industry | 7 | 2019 | 791 | 0.620 |
Why?
|
Medicare Part C | 5 | 2022 | 333 | 0.620 |
Why?
|
Tobacco Use Cessation | 2 | 2017 | 100 | 0.600 |
Why?
|
Health Care Costs | 11 | 2021 | 3239 | 0.600 |
Why?
|
Cost Control | 7 | 2019 | 627 | 0.600 |
Why?
|
Economic Competition | 4 | 2009 | 223 | 0.600 |
Why?
|
Cost Savings | 5 | 2020 | 904 | 0.590 |
Why?
|
Ambulatory Care | 10 | 2024 | 2780 | 0.590 |
Why?
|
Alcohol-Related Disorders | 1 | 2020 | 243 | 0.590 |
Why?
|
Central Nervous System Stimulants | 3 | 2024 | 1168 | 0.580 |
Why?
|
Healthcare Disparities | 8 | 2023 | 3414 | 0.540 |
Why?
|
Legislation, Medical | 2 | 2022 | 99 | 0.540 |
Why?
|
Managed Competition | 1 | 2016 | 33 | 0.540 |
Why?
|
Eligibility Determination | 3 | 2009 | 421 | 0.530 |
Why?
|
Adult | 75 | 2024 | 223317 | 0.520 |
Why?
|
Quality of Health Care | 14 | 2018 | 4306 | 0.510 |
Why?
|
Female | 118 | 2024 | 396660 | 0.510 |
Why?
|
Male | 109 | 2024 | 364203 | 0.510 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 5 | 2024 | 3724 | 0.510 |
Why?
|
Contracts | 1 | 2015 | 60 | 0.500 |
Why?
|
Aged | 81 | 2024 | 171319 | 0.490 |
Why?
|
Long-Term Care | 3 | 2022 | 631 | 0.490 |
Why?
|
Interviews as Topic | 8 | 2023 | 2741 | 0.490 |
Why?
|
Home Care Agencies | 1 | 2015 | 17 | 0.480 |
Why?
|
Young Adult | 33 | 2024 | 59980 | 0.480 |
Why?
|
Skilled Nursing Facilities | 4 | 2022 | 405 | 0.480 |
Why?
|
Prisons | 2 | 2016 | 178 | 0.480 |
Why?
|
Middle Aged | 75 | 2024 | 223233 | 0.470 |
Why?
|
Alcohol Deterrents | 2 | 2024 | 49 | 0.460 |
Why?
|
Antimanic Agents | 3 | 2014 | 524 | 0.460 |
Why?
|
Health Care Reform | 5 | 2020 | 1256 | 0.460 |
Why?
|
United States Food and Drug Administration | 6 | 2013 | 1672 | 0.450 |
Why?
|
Hospitals, General | 1 | 2018 | 804 | 0.440 |
Why?
|
Delivery of Health Care | 4 | 2021 | 5363 | 0.440 |
Why?
|
Drug and Narcotic Control | 2 | 2020 | 145 | 0.440 |
Why?
|
Health Services | 3 | 2017 | 755 | 0.430 |
Why?
|
Coronavirus Infections | 3 | 2020 | 3112 | 0.420 |
Why?
|
Pneumonia, Viral | 3 | 2020 | 3234 | 0.420 |
Why?
|
Adjustment Disorders | 1 | 2013 | 68 | 0.420 |
Why?
|
Cholinesterase Inhibitors | 1 | 2014 | 242 | 0.410 |
Why?
|
Poverty | 7 | 2022 | 2719 | 0.410 |
Why?
|
Adolescent | 34 | 2024 | 89046 | 0.400 |
Why?
|
Terminally Ill | 2 | 2014 | 240 | 0.400 |
Why?
|
Residential Facilities | 1 | 2011 | 41 | 0.380 |
Why?
|
Insurance, Health, Reimbursement | 3 | 2015 | 388 | 0.380 |
Why?
|
Costs and Cost Analysis | 8 | 2023 | 1666 | 0.380 |
Why?
|
Drug Therapy | 1 | 2014 | 504 | 0.370 |
Why?
|
Medication Adherence | 6 | 2020 | 2191 | 0.370 |
Why?
|
Provider-Sponsored Organizations | 2 | 2001 | 12 | 0.360 |
Why?
|
Outpatients | 4 | 2024 | 1600 | 0.360 |
Why?
|
Patents as Topic | 2 | 2009 | 111 | 0.350 |
Why?
|
Quality Assurance, Health Care | 4 | 2015 | 2174 | 0.350 |
Why?
|
Physician Assistants | 2 | 2023 | 190 | 0.350 |
Why?
|
Health Services Research | 7 | 2020 | 1815 | 0.350 |
Why?
|
Health Care Sector | 4 | 2017 | 196 | 0.330 |
Why?
|
Hospitalization | 8 | 2021 | 10815 | 0.330 |
Why?
|
Reimbursement Mechanisms | 3 | 2013 | 670 | 0.330 |
Why?
|
Cross-Sectional Studies | 18 | 2024 | 26325 | 0.330 |
Why?
|
Depression, Postpartum | 2 | 2011 | 355 | 0.320 |
Why?
|
Physician-Patient Relations | 7 | 2014 | 3266 | 0.320 |
Why?
|
Health Policy | 7 | 2015 | 2698 | 0.310 |
Why?
|
Guideline Adherence | 3 | 2016 | 2232 | 0.310 |
Why?
|
Occupational Health Services | 1 | 2009 | 149 | 0.300 |
Why?
|
Medicare Part B | 2 | 2022 | 116 | 0.300 |
Why?
|
Episode of Care | 2 | 1999 | 127 | 0.300 |
Why?
|
Schizophrenia | 4 | 2020 | 6977 | 0.300 |
Why?
|
Fees, Pharmaceutical | 3 | 2020 | 66 | 0.280 |
Why?
|
Massachusetts | 9 | 2018 | 8890 | 0.280 |
Why?
|
Health Services for the Aged | 1 | 2010 | 264 | 0.280 |
Why?
|
Aged, 80 and over | 29 | 2022 | 59548 | 0.280 |
Why?
|
Antineoplastic Agents | 5 | 2022 | 13650 | 0.270 |
Why?
|
Depressive Disorder, Major | 5 | 2013 | 4813 | 0.270 |
Why?
|
Antidepressive Agents, Second-Generation | 1 | 2009 | 491 | 0.260 |
Why?
|
Behavioral Medicine | 2 | 2008 | 49 | 0.260 |
Why?
|
Physicians | 5 | 2022 | 4593 | 0.250 |
Why?
|
Patient Care | 1 | 2011 | 628 | 0.250 |
Why?
|
Home Care Services | 4 | 2020 | 659 | 0.240 |
Why?
|
Emergency Service, Hospital | 6 | 2023 | 7871 | 0.240 |
Why?
|
Subacute Care | 2 | 2017 | 187 | 0.230 |
Why?
|
Qualitative Research | 4 | 2024 | 3139 | 0.230 |
Why?
|
Patient Readmission | 2 | 2017 | 3283 | 0.230 |
Why?
|
Behavior Therapy | 2 | 2001 | 886 | 0.220 |
Why?
|
Longitudinal Studies | 7 | 2024 | 14766 | 0.220 |
Why?
|
Logistic Models | 9 | 2018 | 13284 | 0.220 |
Why?
|
Patient Transfer | 1 | 2010 | 788 | 0.210 |
Why?
|
Rural Population | 5 | 2021 | 2321 | 0.210 |
Why?
|
Lung Neoplasms | 8 | 2017 | 13491 | 0.210 |
Why?
|
Continuity of Patient Care | 3 | 2017 | 1078 | 0.210 |
Why?
|
Inflation, Economic | 1 | 2022 | 30 | 0.200 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2020 | 686 | 0.200 |
Why?
|
Cardiovascular Agents | 3 | 2017 | 849 | 0.200 |
Why?
|
Cohort Studies | 17 | 2023 | 41718 | 0.200 |
Why?
|
Substance Abuse Treatment Centers | 2 | 2020 | 155 | 0.200 |
Why?
|
Advanced Practice Nursing | 1 | 2022 | 18 | 0.200 |
Why?
|
Drug Utilization Review | 4 | 2009 | 248 | 0.200 |
Why?
|
Health Behavior | 3 | 2012 | 2650 | 0.200 |
Why?
|
Patient Education as Topic | 2 | 2009 | 2337 | 0.200 |
Why?
|
Private Sector | 5 | 2018 | 397 | 0.200 |
Why?
|
United States Department of Veterans Affairs | 2 | 2023 | 937 | 0.190 |
Why?
|
Retrospective Studies | 16 | 2024 | 81659 | 0.180 |
Why?
|
Social Work, Psychiatric | 1 | 2020 | 21 | 0.180 |
Why?
|
Utilization Review | 4 | 2015 | 381 | 0.180 |
Why?
|
Psychotherapy, Group | 1 | 2024 | 417 | 0.180 |
Why?
|
Congresses as Topic | 1 | 2006 | 812 | 0.180 |
Why?
|
Health Care Surveys | 8 | 2016 | 2428 | 0.180 |
Why?
|
Rural Health Services | 2 | 2021 | 393 | 0.180 |
Why?
|
Child | 15 | 2024 | 80771 | 0.170 |
Why?
|
Depressive Disorder | 4 | 2024 | 3721 | 0.170 |
Why?
|
Pennsylvania | 5 | 2019 | 615 | 0.160 |
Why?
|
Practice Management | 1 | 1999 | 37 | 0.160 |
Why?
|
Accounting | 1 | 1999 | 25 | 0.160 |
Why?
|
Policy | 1 | 2023 | 513 | 0.160 |
Why?
|
New Jersey | 3 | 2011 | 296 | 0.160 |
Why?
|
Length of Stay | 2 | 2021 | 6489 | 0.150 |
Why?
|
Hospitals, Psychiatric | 1 | 2019 | 317 | 0.150 |
Why?
|
Data Collection | 4 | 2011 | 3321 | 0.150 |
Why?
|
Efficiency, Organizational | 2 | 2007 | 697 | 0.150 |
Why?
|
Women's Health Services | 1 | 1998 | 87 | 0.150 |
Why?
|
Attitude to Death | 2 | 2012 | 400 | 0.150 |
Why?
|
Truth Disclosure | 2 | 2014 | 434 | 0.140 |
Why?
|
Delivery of Health Care, Integrated | 3 | 2014 | 951 | 0.140 |
Why?
|
Substance Abuse Detection | 1 | 2020 | 301 | 0.140 |
Why?
|
Depression | 6 | 2023 | 8234 | 0.140 |
Why?
|
Marketing | 2 | 2012 | 225 | 0.140 |
Why?
|
Group Practice | 2 | 2013 | 148 | 0.140 |
Why?
|
Quality Improvement | 3 | 2018 | 3854 | 0.140 |
Why?
|
Methadone | 3 | 2024 | 317 | 0.140 |
Why?
|
Patient Compliance | 1 | 2007 | 2697 | 0.140 |
Why?
|
Hypoglycemic Agents | 2 | 2020 | 3108 | 0.140 |
Why?
|
Health Maintenance Organizations | 2 | 2011 | 656 | 0.140 |
Why?
|
Needs Assessment | 2 | 2020 | 1141 | 0.140 |
Why?
|
Health Planning | 3 | 2023 | 233 | 0.140 |
Why?
|
Pain | 2 | 2022 | 5101 | 0.140 |
Why?
|
Critical Care | 1 | 2009 | 2714 | 0.130 |
Why?
|
Physicians, Primary Care | 1 | 2023 | 623 | 0.130 |
Why?
|
Naltrexone | 3 | 2023 | 319 | 0.130 |
Why?
|
Financing, Personal | 4 | 2012 | 310 | 0.130 |
Why?
|
Politics | 3 | 2010 | 822 | 0.130 |
Why?
|
Quality Indicators, Health Care | 5 | 2017 | 1804 | 0.130 |
Why?
|
Geography | 1 | 2018 | 651 | 0.130 |
Why?
|
Insurance, Psychiatric | 2 | 2015 | 66 | 0.130 |
Why?
|
Psychotherapy | 2 | 2020 | 1653 | 0.130 |
Why?
|
Criminal Law | 1 | 2016 | 97 | 0.130 |
Why?
|
Income | 5 | 2021 | 1877 | 0.130 |
Why?
|
Medicine | 2 | 2022 | 944 | 0.130 |
Why?
|
Models, Psychological | 1 | 2020 | 823 | 0.130 |
Why?
|
Propylamines | 2 | 2013 | 161 | 0.120 |
Why?
|
Communication | 5 | 2014 | 3904 | 0.120 |
Why?
|
State Health Plans | 2 | 2011 | 220 | 0.120 |
Why?
|
Government Regulation | 1 | 2019 | 525 | 0.120 |
Why?
|
Patient Discharge | 4 | 2023 | 3467 | 0.120 |
Why?
|
Perception | 1 | 2021 | 1205 | 0.120 |
Why?
|
Adrenergic Uptake Inhibitors | 2 | 2013 | 186 | 0.120 |
Why?
|
Neoplasms | 8 | 2022 | 22350 | 0.120 |
Why?
|
Etoposide | 1 | 2016 | 639 | 0.120 |
Why?
|
Patient Admission | 3 | 2010 | 1364 | 0.120 |
Why?
|
Drug Approval | 4 | 2015 | 820 | 0.110 |
Why?
|
Angiogenesis Inhibitors | 2 | 2015 | 2055 | 0.110 |
Why?
|
Marketing of Health Services | 1 | 2015 | 151 | 0.110 |
Why?
|
Antithrombins | 1 | 2016 | 294 | 0.110 |
Why?
|
Choice Behavior | 2 | 2023 | 848 | 0.110 |
Why?
|
Patient Acceptance of Health Care | 3 | 2023 | 3232 | 0.110 |
Why?
|
Clinical Competence | 1 | 2009 | 4859 | 0.110 |
Why?
|
Carboplatin | 1 | 2016 | 790 | 0.110 |
Why?
|
Negotiating | 2 | 2023 | 152 | 0.100 |
Why?
|
Primary Health Care | 4 | 2022 | 4746 | 0.100 |
Why?
|
Child, Preschool | 4 | 2024 | 42606 | 0.100 |
Why?
|
Amphetamines | 1 | 2013 | 142 | 0.100 |
Why?
|
Urban Population | 1 | 2020 | 2044 | 0.100 |
Why?
|
Prisoners | 1 | 2015 | 315 | 0.100 |
Why?
|
Delusions | 1 | 2014 | 300 | 0.100 |
Why?
|
France | 1 | 2013 | 496 | 0.100 |
Why?
|
General Practice | 1 | 2013 | 101 | 0.100 |
Why?
|
Cyclohexanecarboxylic Acids | 1 | 2012 | 139 | 0.100 |
Why?
|
Hallucinations | 1 | 2014 | 373 | 0.090 |
Why?
|
Florida | 1 | 2013 | 417 | 0.090 |
Why?
|
Decision Making | 5 | 2023 | 3951 | 0.090 |
Why?
|
Administration, Oral | 4 | 2020 | 4026 | 0.090 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2016 | 454 | 0.090 |
Why?
|
Public Health | 2 | 2021 | 2681 | 0.090 |
Why?
|
Commerce | 2 | 2023 | 614 | 0.090 |
Why?
|
Amines | 1 | 2012 | 280 | 0.090 |
Why?
|
Hospitals, Maternity | 1 | 2011 | 31 | 0.090 |
Why?
|
Health Services Needs and Demand | 2 | 2013 | 1405 | 0.090 |
Why?
|
Time Factors | 9 | 2023 | 40154 | 0.090 |
Why?
|
Regression Analysis | 5 | 2013 | 6331 | 0.090 |
Why?
|
Disability Evaluation | 2 | 2017 | 1829 | 0.090 |
Why?
|
Medical Assistance | 1 | 2011 | 108 | 0.090 |
Why?
|
Off-Label Use | 1 | 2012 | 185 | 0.090 |
Why?
|
Organizational Affiliation | 1 | 2010 | 34 | 0.090 |
Why?
|
Health Care Rationing | 2 | 2013 | 435 | 0.090 |
Why?
|
Organizational Case Studies | 2 | 2001 | 301 | 0.090 |
Why?
|
Emergency Services, Psychiatric | 1 | 2010 | 65 | 0.090 |
Why?
|
Tobacco Use Disorder | 1 | 2016 | 708 | 0.090 |
Why?
|
Risk Assessment | 4 | 2012 | 24299 | 0.090 |
Why?
|
Social Justice | 2 | 2015 | 487 | 0.090 |
Why?
|
Cisplatin | 1 | 2016 | 1656 | 0.090 |
Why?
|
Population Groups | 1 | 2011 | 209 | 0.090 |
Why?
|
Conflict of Interest | 1 | 2015 | 556 | 0.090 |
Why?
|
Ambulatory Care Facilities | 1 | 2016 | 939 | 0.080 |
Why?
|
Sex Factors | 2 | 2016 | 10622 | 0.080 |
Why?
|
Aggression | 1 | 2014 | 748 | 0.080 |
Why?
|
Legislation as Topic | 1 | 2009 | 76 | 0.080 |
Why?
|
Risk Sharing, Financial | 2 | 2000 | 47 | 0.080 |
Why?
|
Health Facilities | 2 | 2020 | 578 | 0.080 |
Why?
|
Missouri | 2 | 2016 | 113 | 0.080 |
Why?
|
Awareness | 2 | 2014 | 653 | 0.080 |
Why?
|
Forecasting | 2 | 2016 | 2936 | 0.080 |
Why?
|
Hospital Costs | 3 | 2010 | 956 | 0.080 |
Why?
|
Colorectal Neoplasms | 3 | 2014 | 6966 | 0.080 |
Why?
|
Policy Making | 2 | 2005 | 546 | 0.080 |
Why?
|
Diffusion of Innovation | 1 | 2013 | 724 | 0.080 |
Why?
|
Counseling | 1 | 2016 | 1553 | 0.070 |
Why?
|
Tamoxifen | 1 | 2012 | 966 | 0.070 |
Why?
|
Drug Compounding | 1 | 2009 | 236 | 0.070 |
Why?
|
Medical Oncology | 2 | 2018 | 2341 | 0.070 |
Why?
|
Frail Elderly | 1 | 2013 | 781 | 0.070 |
Why?
|
Benzamides | 1 | 2013 | 1376 | 0.070 |
Why?
|
Community Mental Health Services | 1 | 2011 | 387 | 0.070 |
Why?
|
Preferred Provider Organizations | 1 | 2007 | 36 | 0.070 |
Why?
|
Preventive Health Services | 2 | 2011 | 570 | 0.070 |
Why?
|
Hyperlipidemias | 1 | 2013 | 771 | 0.070 |
Why?
|
Psychotherapy, Brief | 1 | 2009 | 118 | 0.070 |
Why?
|
Models, Organizational | 1 | 2011 | 548 | 0.070 |
Why?
|
Federal Government | 2 | 2006 | 266 | 0.070 |
Why?
|
New England | 1 | 2010 | 1058 | 0.070 |
Why?
|
Survivors | 2 | 2009 | 2381 | 0.070 |
Why?
|
Confidence Intervals | 1 | 2013 | 2920 | 0.070 |
Why?
|
Institutionalization | 1 | 2007 | 108 | 0.070 |
Why?
|
Chemistry, Pharmaceutical | 1 | 2008 | 273 | 0.070 |
Why?
|
National Health Insurance, United States | 1 | 2007 | 100 | 0.070 |
Why?
|
Health Personnel | 1 | 2020 | 3387 | 0.070 |
Why?
|
Personnel Staffing and Scheduling | 1 | 2010 | 497 | 0.070 |
Why?
|
Cognition | 1 | 2024 | 7059 | 0.070 |
Why?
|
Patient Care Planning | 1 | 2012 | 903 | 0.070 |
Why?
|
Pharmacies | 1 | 2008 | 171 | 0.070 |
Why?
|
gamma-Aminobutyric Acid | 1 | 2012 | 1139 | 0.070 |
Why?
|
Insurance Carriers | 2 | 2018 | 159 | 0.060 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2020 | 12250 | 0.060 |
Why?
|
Insulin | 1 | 2020 | 6602 | 0.060 |
Why?
|
Aftercare | 3 | 2023 | 915 | 0.060 |
Why?
|
Diabetes Mellitus | 2 | 2015 | 5886 | 0.060 |
Why?
|
Ticlopidine | 1 | 2010 | 729 | 0.060 |
Why?
|
Health Status | 2 | 2010 | 4091 | 0.060 |
Why?
|
Neurology | 1 | 2013 | 785 | 0.060 |
Why?
|
Risk Adjustment | 1 | 2008 | 597 | 0.060 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2013 | 2428 | 0.060 |
Why?
|
Academic Medical Centers | 1 | 2015 | 2783 | 0.060 |
Why?
|
Angiotensin II Type 1 Receptor Blockers | 1 | 2007 | 428 | 0.060 |
Why?
|
Linear Models | 1 | 2014 | 5875 | 0.060 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2012 | 1536 | 0.060 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2014 | 6023 | 0.060 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 3 | 2008 | 1515 | 0.060 |
Why?
|
Trust | 1 | 2009 | 532 | 0.060 |
Why?
|
Databases, Factual | 2 | 2016 | 8068 | 0.060 |
Why?
|
Proportional Hazards Models | 3 | 2013 | 12536 | 0.060 |
Why?
|
Probability | 3 | 2017 | 2476 | 0.050 |
Why?
|
Physician Incentive Plans | 1 | 2005 | 165 | 0.050 |
Why?
|
Antihypertensive Agents | 2 | 2017 | 2030 | 0.050 |
Why?
|
Cardiovascular Diseases | 2 | 2024 | 15645 | 0.050 |
Why?
|
Employment | 1 | 2009 | 1110 | 0.050 |
Why?
|
Government Programs | 1 | 2005 | 278 | 0.050 |
Why?
|
Piperazines | 1 | 2013 | 2548 | 0.050 |
Why?
|
Prenatal Care | 1 | 2011 | 1158 | 0.050 |
Why?
|
Cost of Illness | 1 | 2013 | 1951 | 0.050 |
Why?
|
Disabled Persons | 1 | 2012 | 1209 | 0.050 |
Why?
|
Medicare Part A | 1 | 2022 | 40 | 0.050 |
Why?
|
Anticonvulsants | 1 | 2012 | 1921 | 0.050 |
Why?
|
Disulfiram | 1 | 2022 | 63 | 0.050 |
Why?
|
Multiple Myeloma | 1 | 2020 | 5186 | 0.050 |
Why?
|
Propensity Score | 3 | 2018 | 1971 | 0.050 |
Why?
|
Protein Kinase Inhibitors | 2 | 2020 | 5693 | 0.050 |
Why?
|
Public Sector | 2 | 2017 | 266 | 0.050 |
Why?
|
Breast Neoplasms | 3 | 2015 | 21178 | 0.050 |
Why?
|
Independent Practice Associations | 1 | 2001 | 21 | 0.050 |
Why?
|
Combined Modality Therapy | 2 | 2011 | 8535 | 0.050 |
Why?
|
Pyrimidines | 1 | 2013 | 3044 | 0.050 |
Why?
|
Health Education | 1 | 2008 | 1058 | 0.050 |
Why?
|
Child Health Services | 1 | 2007 | 645 | 0.050 |
Why?
|
Neuropsychological Tests | 1 | 2014 | 7121 | 0.050 |
Why?
|
Multivariate Analysis | 4 | 2011 | 12069 | 0.050 |
Why?
|
Activities of Daily Living | 2 | 2007 | 2429 | 0.050 |
Why?
|
Oregon | 1 | 2001 | 148 | 0.050 |
Why?
|
Drug Information Services | 2 | 2012 | 51 | 0.050 |
Why?
|
Methylphenidate | 1 | 2005 | 480 | 0.050 |
Why?
|
Pediatrics | 2 | 2013 | 3621 | 0.040 |
Why?
|
Total Quality Management | 1 | 2002 | 266 | 0.040 |
Why?
|
Naloxone | 1 | 2023 | 372 | 0.040 |
Why?
|
United States Substance Abuse and Mental Health Services Administration | 1 | 2020 | 21 | 0.040 |
Why?
|
Benchmarking | 1 | 2007 | 1056 | 0.040 |
Why?
|
Cognition Disorders | 1 | 2014 | 3968 | 0.040 |
Why?
|
Job Description | 1 | 2000 | 61 | 0.040 |
Why?
|
Hospitals | 2 | 2017 | 3883 | 0.040 |
Why?
|
Evidence-Based Medicine | 3 | 2013 | 3700 | 0.040 |
Why?
|
Social Security | 2 | 2012 | 101 | 0.040 |
Why?
|
Drug Substitution | 2 | 2012 | 292 | 0.040 |
Why?
|
Attitude to Health | 1 | 2008 | 2023 | 0.040 |
Why?
|
Transportation of Patients | 1 | 2020 | 177 | 0.040 |
Why?
|
Capital Financing | 1 | 1999 | 58 | 0.040 |
Why?
|
Smoking | 1 | 2016 | 9081 | 0.040 |
Why?
|
Specialization | 1 | 2024 | 778 | 0.040 |
Why?
|
For-Profit Insurance Plans | 1 | 2018 | 8 | 0.040 |
Why?
|
Socioeconomic Factors | 4 | 2018 | 7848 | 0.040 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2017 | 3249 | 0.040 |
Why?
|
Prescriptions | 1 | 2021 | 388 | 0.040 |
Why?
|
Health Status Disparities | 1 | 2010 | 1882 | 0.040 |
Why?
|
Proton Pump Inhibitors | 1 | 2003 | 551 | 0.040 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2012 | 4054 | 0.040 |
Why?
|
Office Visits | 1 | 2022 | 595 | 0.040 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2010 | 2764 | 0.040 |
Why?
|
Fumarates | 1 | 2018 | 132 | 0.040 |
Why?
|
Insurance Claim Reporting | 1 | 2018 | 166 | 0.040 |
Why?
|
Drug Interactions | 2 | 2012 | 1419 | 0.040 |
Why?
|
Multi-Institutional Systems | 1 | 2017 | 43 | 0.040 |
Why?
|
Family Health | 1 | 2022 | 1254 | 0.040 |
Why?
|
Health Promotion | 1 | 2009 | 2210 | 0.040 |
Why?
|
Prospective Studies | 7 | 2018 | 54886 | 0.030 |
Why?
|
Minority Groups | 1 | 2024 | 1214 | 0.030 |
Why?
|
Licensure | 1 | 2017 | 128 | 0.030 |
Why?
|
Age Factors | 2 | 2010 | 18401 | 0.030 |
Why?
|
South Carolina | 1 | 2016 | 113 | 0.030 |
Why?
|
Cost-Benefit Analysis | 3 | 2010 | 5537 | 0.030 |
Why?
|
Amides | 1 | 2018 | 451 | 0.030 |
Why?
|
Patient Preference | 1 | 2023 | 947 | 0.030 |
Why?
|
Attitude of Health Personnel | 3 | 2020 | 3928 | 0.030 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 11872 | 0.030 |
Why?
|
Patient Satisfaction | 2 | 2024 | 3488 | 0.030 |
Why?
|
Chronic Disease | 3 | 2022 | 9362 | 0.030 |
Why?
|
Treatment Outcome | 5 | 2016 | 65295 | 0.030 |
Why?
|
Iowa | 1 | 2014 | 100 | 0.030 |
Why?
|
Culture | 1 | 2018 | 622 | 0.030 |
Why?
|
Capital Expenditures | 1 | 1994 | 27 | 0.030 |
Why?
|
Alabama | 1 | 2014 | 112 | 0.030 |
Why?
|
Neoplasm Metastasis | 2 | 2015 | 4892 | 0.030 |
Why?
|
North Carolina | 1 | 2014 | 329 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 2018 | 2227 | 0.030 |
Why?
|
Comorbidity | 2 | 2024 | 10582 | 0.030 |
Why?
|
Guanfacine | 1 | 2013 | 50 | 0.030 |
Why?
|
Peer Group | 1 | 2018 | 702 | 0.030 |
Why?
|
Infant, Newborn | 1 | 2013 | 26396 | 0.030 |
Why?
|
Odds Ratio | 2 | 2018 | 9660 | 0.030 |
Why?
|
Random Allocation | 1 | 2017 | 2394 | 0.030 |
Why?
|
Compensation and Redress | 1 | 2012 | 66 | 0.020 |
Why?
|
Clonidine | 1 | 2013 | 170 | 0.020 |
Why?
|
Adrenergic alpha-2 Receptor Agonists | 1 | 2013 | 92 | 0.020 |
Why?
|
Bayes Theorem | 1 | 2020 | 2353 | 0.020 |
Why?
|
SEER Program | 1 | 2017 | 1444 | 0.020 |
Why?
|
Health Planning Support | 1 | 2011 | 8 | 0.020 |
Why?
|
Follow-Up Studies | 2 | 2011 | 39317 | 0.020 |
Why?
|
Dopamine Uptake Inhibitors | 1 | 2013 | 286 | 0.020 |
Why?
|
Immunologic Factors | 1 | 2020 | 1592 | 0.020 |
Why?
|
Quality of Life | 2 | 2010 | 13485 | 0.020 |
Why?
|
Bupropion | 1 | 2013 | 303 | 0.020 |
Why?
|
Advance Directives | 1 | 2012 | 249 | 0.020 |
Why?
|
Infant | 1 | 2013 | 36485 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2022 | 10393 | 0.020 |
Why?
|
Models, Statistical | 1 | 2005 | 5098 | 0.020 |
Why?
|
Drug Labeling | 1 | 2012 | 251 | 0.020 |
Why?
|
Program Evaluation | 1 | 1999 | 2505 | 0.020 |
Why?
|
Risk Factors | 2 | 2014 | 74886 | 0.020 |
Why?
|
California | 1 | 2014 | 1439 | 0.020 |
Why?
|
Mass Media | 1 | 2012 | 303 | 0.020 |
Why?
|
Alcohol Drinking | 1 | 2022 | 4045 | 0.020 |
Why?
|
Asthma | 1 | 2008 | 6268 | 0.020 |
Why?
|
Myocardial Infarction | 1 | 2010 | 11513 | 0.020 |
Why?
|
Data Interpretation, Statistical | 1 | 1999 | 2698 | 0.020 |
Why?
|
Risk Management | 1 | 2012 | 558 | 0.020 |
Why?
|
Aromatase Inhibitors | 1 | 2012 | 519 | 0.020 |
Why?
|
Organizations, Nonprofit | 1 | 2009 | 105 | 0.020 |
Why?
|
Diagnosis-Related Groups | 1 | 2010 | 445 | 0.020 |
Why?
|
Postnatal Care | 1 | 2011 | 273 | 0.020 |
Why?
|
Myocardial Revascularization | 1 | 2012 | 795 | 0.020 |
Why?
|
Medical Order Entry Systems | 1 | 2013 | 523 | 0.020 |
Why?
|
Recurrence | 2 | 2010 | 8504 | 0.020 |
Why?
|
Prognosis | 3 | 2014 | 29963 | 0.020 |
Why?
|
Expert Testimony | 1 | 2009 | 266 | 0.020 |
Why?
|
Palliative Care | 2 | 2012 | 3641 | 0.020 |
Why?
|
Pharmacists | 1 | 2009 | 261 | 0.020 |
Why?
|
Drug Monitoring | 1 | 2012 | 963 | 0.020 |
Why?
|
Alzheimer Disease | 1 | 2007 | 8717 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2016 | 6513 | 0.020 |
Why?
|
Financing, Government | 1 | 2009 | 473 | 0.020 |
Why?
|
Disease Management | 1 | 2016 | 2531 | 0.020 |
Why?
|
Calcium Channel Blockers | 1 | 2008 | 688 | 0.010 |
Why?
|
Multicenter Studies as Topic | 1 | 2010 | 1733 | 0.010 |
Why?
|
Models, Theoretical | 1 | 2016 | 3561 | 0.010 |
Why?
|
Practice Guidelines as Topic | 2 | 2012 | 7435 | 0.010 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2008 | 1243 | 0.010 |
Why?
|
Health Status Indicators | 1 | 2007 | 969 | 0.010 |
Why?
|
Anticoagulants | 1 | 2017 | 4854 | 0.010 |
Why?
|
Quality-Adjusted Life Years | 1 | 2008 | 1741 | 0.010 |
Why?
|
Thrombolytic Therapy | 1 | 2010 | 2054 | 0.010 |
Why?
|
Patient Selection | 1 | 2012 | 4256 | 0.010 |
Why?
|
Consensus | 1 | 2008 | 3207 | 0.010 |
Why?
|
Feedback | 1 | 2002 | 797 | 0.010 |
Why?
|
Prevalence | 1 | 2015 | 15851 | 0.010 |
Why?
|
Decision Support Techniques | 1 | 2007 | 2006 | 0.010 |
Why?
|
Competitive Bidding | 1 | 1996 | 16 | 0.010 |
Why?
|
Capitation Fee | 1 | 1996 | 115 | 0.010 |
Why?
|
Guidelines as Topic | 1 | 2002 | 1396 | 0.010 |
Why?
|
Disease Progression | 1 | 2012 | 13646 | 0.010 |
Why?
|
Referral and Consultation | 1 | 2007 | 3618 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2007 | 14672 | 0.010 |
Why?
|
Anxiety | 1 | 2007 | 4670 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2008 | 15925 | 0.010 |
Why?
|
Pregnancy | 1 | 2011 | 30238 | 0.000 |
Why?
|
Case-Control Studies | 1 | 2005 | 22254 | 0.000 |
Why?
|